Oncosil Medical
Oncosil Medical is a medical device company focused on the development and commercialization of innovative cancer treatments. Their primary product, OncoSil, is a brachytherapy device containing radioactive phosphorus-32, designed for the treatment of locally advanced pancreatic cancer. The company aims to improve patient outcomes and quality of life through targeted radiation therapy.
Short position
Oncosil Medical (ASX:OSL) has 0.00% of its shares on issue reported as short positions as of 5 Oct 2026, or about 66 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.69% in December 2024. OSL is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Oncosil Medical (OSL) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $1.7Mvs $1.2M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- NPAT
- −$10.9Mvs −$15.1M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- −$0.48T (source: Derived: trailing 12 months at year end)vs −$1.37 (FY25)
- Derived: trailing 12 months at year end, as at 29 Sep 2026
- Rev YoY
- +43.9%FY
- EPS YoY
- n/aTTM
- Derived: trailing 12 months at year end
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 9 Oct 2026
- Gross margin
- −39.9%
- Operating margin
- −859.2%
- Net margin
- −644.5%
- FCF margin
- −621.6%
- ROE
- −268.2%
- ROA
- −124.4%
- FCF conversion
- n/a
- Net cash (excl. leases)
- $6.5M
- Net debt / EBITDA
- n/a
- Current ratio
- 1.8×
- Interest cover
- −1,100.1×
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (listed unit is not one ordinary share)
- P/E
- n/a (listed unit is not one ordinary share)
- P/B
- n/a (listed unit is not one ordinary share)
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $1.7M | $1.2M | $516.6K | $367.7K |
| Gross profit | −$672.3K | −$1.1M | −$993.1K | −$1.2M |
| Operating income | −$14.5M | −$15.5M | −$13.1M | −$12.7M |
| EBITDA | −$10.8M | −$15.1M | −$12.3M | −$11.2M |
| EBIT | −$10.8M | −$15.1M | −$12.4M | −$11.3M |
| Interest expense | $13.2K | $722 | $563 | $5 |
| Pretax income | −$10.9M | −$15.1M | −$12.4M | −$11.3M |
| Tax | $0 | $0 | $0 | $0 |
| NPAT | −$10.9M | −$15.1M | −$12.4M | −$11.3M |
| Net interest income | $122.8K | $90.0K | $62.6K | $51.7K |
| EPS basic | −$0.48T (source: Derived: trailing 12 months at year end) | −$1.37 | −$2.23 | −$3.76 |
| EPS diluted | −$0.48T (source: Derived: trailing 12 months at year end) | −$1.37 | −$2.23 | −$3.76 |
| Shares | 30.9M | 14.3M | 8.4M | 5.3M |
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Appendix 4E and Annual ReportAnnual Results28 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report28 Apr 2026via asx_announcements
- Appendix 4D and Half Year AccountsHalf Year Results24 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Jan 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report30 Oct 2025via asx_announcements
- Annual Report (Typeset)Annual Report23 Oct 2025via asx_announcements
- Appendix 4E and Annual ReportAnnual Results29 Aug 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Jul 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow Report AddendumQuarterly Report2 May 2025via asx_announcements
Showing 10 of 31 reports